As of July 31, 2025, Caplin Point Laboratories Ltd (CAPLIPOINT) is trading near ₹2,085, showing a mixed but steady performance with some recent price fluctuations around this level. The stock briefly touched intraday highs around ₹2,095 and lows near ₹2,030, maintaining support in the ₹2,030–₹2,055 range. Market capitalization stands broadly near ₹15,590 crore.
Caplin Point benefits from solid fundamentals in the pharmaceutical sector, supported by consistent revenue growth and operational efficiencies. The price-to-earnings ratio sits around 29, while the price-to-book ratio is approximately 5.5, indicating premium valuation relative to book but in line with sector expectations. Dividend yield is low at about 0.15%, reflecting the company’s focus on growth over payout.
Technically, the stock tends to hover above its medium-term moving averages like the 50-day and 200-day SMAs, showing cautious bullish momentum, although near-term volatility remains. Trading volumes are moderate, and the relative strength index is near mid-range levels, suggesting balanced momentum without overbought or oversold extremes.
Overall, Caplin Point Laboratories currently reflects steady fundamentals with a valuation premium typical of its pharma peer group, supported by stable trading ranges and positive medium-term technical signals. The near-term outlook remains cautiously optimistic, with key support near ₹2,030 and potential resistance around ₹2,100–₹2,120.
Caplin Point benefits from solid fundamentals in the pharmaceutical sector, supported by consistent revenue growth and operational efficiencies. The price-to-earnings ratio sits around 29, while the price-to-book ratio is approximately 5.5, indicating premium valuation relative to book but in line with sector expectations. Dividend yield is low at about 0.15%, reflecting the company’s focus on growth over payout.
Technically, the stock tends to hover above its medium-term moving averages like the 50-day and 200-day SMAs, showing cautious bullish momentum, although near-term volatility remains. Trading volumes are moderate, and the relative strength index is near mid-range levels, suggesting balanced momentum without overbought or oversold extremes.
Overall, Caplin Point Laboratories currently reflects steady fundamentals with a valuation premium typical of its pharma peer group, supported by stable trading ranges and positive medium-term technical signals. The near-term outlook remains cautiously optimistic, with key support near ₹2,030 and potential resistance around ₹2,100–₹2,120.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.